Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Akums Drugs and Pharmaceuticals's Revenue for the
three
months ended in Jun. 2026 was ₹11,666 Mil. Akums Drugs and Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹7,966 Mil.
Hence, Akums Drugs and Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.46.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Akums Drugs and Pharmaceuticals Receivables Turnover Related Terms
Akums Drugs and Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals Receivables Turnover Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Receivables Turnover of 1.46 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Akums Drugs and Pharmaceuticals and its competitors. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #384 out of 947 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is Akums Drugs and Pharmaceuticals' Receivables Turnover too high?
Akums Drugs and Pharmaceuticals' current Receivables Turnover is 1.46. The Drug Manufacturers industry median Receivables Turnover is 5.08. Akums Drugs and Pharmaceuticals' value of 1.46 is 71.3% below this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #384 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #384 out of 947 companies for Receivables Turnover. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.08. Akums Drugs and Pharmaceuticals' value of 1.46 is 71.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current Receivables Turnover of 1.46 is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current Receivables Turnover is 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Receivables Turnover of 1.46. The current Receivables Turnover is 1.46 and 71.3% below the Drug Manufacturers industry median of 5.08. Akums Drugs and Pharmaceuticals' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Receivables Turnover is 1.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
40GF Score
Get the complete analysis for NSE:AKUMS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
